Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 234

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 234
---
        |     |                 |         |

| (1) | Unless otherwise noted, each option vests 25% on the first anniversary of the grant date, then vests in 36 equal                                                                                                       
 monthly installments thereafter, such that the option is vested on the fourth anniversary of the grant date, subject to the holder continuing to provide services to the Company through each applicable vesting date. |

| (2) | Calculated by multiplying the number of unvested shares by $3.155, the closing price per share of our common 
 stock on Nasdaq on December 31, 2024, the last trading day of 2024.                                          |

| (3) | Each option was granted in respect of amounts payable to such named executive officers under our 2023 bonus plan 
 and was fully vested at grant.                                                                                   |

| (4) | 25% of such restricted stock units will vest on each anniversary of the grant date, subject to the holder 
 continuing to provide services to the Company through each applicable vesting date.                       |

Employment Agreements We have entered into employment agreements with each of Dr. Lennon and Messrs. Giacobello and Ball. Each employment agreement provides for “at will” employment, meaning that either we or the officer may terminate the employment relationship at any time without cause. The material terms of the employment agreements with our 2023 named executive officers are described below. - 163 -

Executive Employment Agreements with David Lennon, Ph.D.

In connection with Dr. Lennon’s appointment as our President and Chief Executive Officer, on September 29, 2023, the Company entered into an
Executive Employment Agreement (the “Lennon Employment Agreement”) with Dr. Lennon. Pursuant to the terms of the Lennon Employment Agreement, Dr. Lennon received an initial annual base salary of $640,000 and is eligible to
receive an annual bonus of up to 60% of his annual base salary upon achievement of performance objectives to be determined by our board of directors or its authorized committee in its sole discretion, with reasonable input from Dr. Lennon.
Dr. Lennon’s current base salary is $659,200. In addition, in 2023, Dr. Lennon received a sign-on bonus of $240,000 consisting of: (1) $100,000 in cash and (2) an award of restricted stock
units (“Lennon RSUs”) covering a number of shares of our common stock with a $140,000 grant date fair value (as determined